01LockMiR PlatformScienceHow LockMiR reprograms tumor behavior upstream of protein targets.
02Clinical DataClinicalPhase 1a results with zero grade 3-4 toxicities and a 56% disease control rate.03ProgramsPipelineThree therapeutic programs across oncology, CNS diseases, and fibrosis.
04LeadershipTeamScientific, clinical, regulatory, and company-building expertise.05NetworkCollaborationsStrategic academic, clinical, and biotech relationships supporting translation.06ResearchPublicationsPeer-reviewed publications and clinical resources from Pherrix and collaborators.07UpdatesNewsCompany announcements and updates will be published here.08Partner With UsContactConnect with Pherrix about partnerships, investment, and collaborations.